Professional
Added to YB: 2024-04-22
Pitch date: 2024-04-10
MRK [bullish]
Merck & Co., Inc.
+1.9%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$298.8B
Pitch Price
$118.60
Price Target
N/A
Dividend
2.81%
EV/EBITDA
11.34
P/E
16.60
EV/Sales
5.15
Sector
Pharmaceuticals
Category
N/A
GreensKeeper Value Fund Portfolio Holding: Merck & Co., Inc.
MRK +21% on FDA nod for Winrevair, 1st disease-modifying PAH drug. Targets root cause in rare disease affecting 40K Americans. Key to offset Keytruda patent cliff in '28, protect future revenue. Clinical trials showed improved lung function & lower fatalities.
Read full article (1 min)